Trial · NCT02415608
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Ibrutinib 420 mg/Day | 0 | Participants | ||
| Overall Response Rate (ORR) | Ibrutinib 560 mg/Day | 0 | Participants | ||
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Adverse event | 3 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Adverse event | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Grade 1 Adverse Event (mild) | 3 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Grade 1 Adverse Event (mild) | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Grade 2 Adverse Event (moderate) | 3 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Grade 2 Adverse Event (moderate) | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Grade 3 Adverse Event (severe) | 2 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Grade 3 Adverse Event (severe) | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Grade 4 Adverse Event (life-threatening) | 0 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Grade 4 Adverse Event (life-threatening) | 0 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Grade 5 Adverse Event (death) | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Grade 5 Adverse Event (death) | 0 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Blood or Lymphatic System Disorder | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Blood or Lymphatic System Disorder | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any Gastrointestinal Disorder | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any Gastrointestinal Disorder | 1 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 420 mg/Day | Any General Disorder | 3 | Participants | |
| Number of Participants With Adverse Events | Ibrutinib 560 mg/Day | Any General Disorder | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02415608/results